



Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 11, 2024 at 7:00 AM EST

BOSTON--(BUSINESS WIRE)--Jan. 11, 2024-- Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET.

To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative.

Following the event, an archived replay of the fireside chat will be available on the investors section of the Company's website at www.verastem.com.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20240111104814/en/>

Investors:

Ryan Porter
Argot Partners
+1 212-600-1902
ryan.porter@argotpartners.com

Media:

Lisa Buffington
Corporate Communications
+1 781-292-4502
lbuffington@verastem.com

Source: Verastem Oncology